РОЗРОБКА МЕТОДИКИ КІЛЬКІСНОГО ВИЗНАЧЕННЯ ДЛЯ ПОСТАДІЙНОГО КОНТРОЛЮ ВИРОБНИЦТВА ТАБЛЕТОК «ГІПЕРТРИЛ»
DOI:
https://doi.org/10.11603/2312-0967.2015.2.4752Abstract
L.I.Kucherenko, N.V.Parnyuk, Z.B.Moryak
DEVELOPMENT OF QUANTITATIVE DETERMINATION METODS FOR THE STEPWISE CONTROL OF "HYPERTRIL" TABLETS PRODUCTION
Zaporizhzhia State Medical University
“Pharmatron” Scientific-and-Production Corporation
Key words: hypertril, tablet mass, tablets, spectrophotometry
Introduction
Last 20-25 years inUkraineare characterized by unfavorable demographic situation, a significant increase in morbidity and mortality. The deterioration ofUkrainepopulation health is often caused by cardiovascular diseases. Therefore, the development of treatments for diseases of the cardiovascular system is the actual problem of modern medicine and pharmacy. This led to the creation of fundamentally new antianginal and antihypertensive medication of original structure, which will have a minimum of side effects. At the Department of Pharmaceutical Chemistry of Zaporizhzhia State Medical University in collaboration with the SPC "Pharmatron" under the direction of Professor Mazur I.A, a new original compound - bromide 1-β-phenylethyl-4-amino-1,2,4-triazole (hypertril) is received and shows antihypertensive, antiischemic and antioxidant properties. Most drugs for the treatment of cardiovascular disease are used in pill form. Therefore, the new elected rational drug dosage form is a pill.
The aim of research
Development of methods of standardization, in particular quantitative content of hypertril in tablet weight by physical and chemical methods.
Materials and methods
During technological research a drug (pill average weight0.15 grams) containing0.02 gof active substance, was developed. During the stepwise control of pill's production the greatest attention is paid to quality control of tablet weight. One of the most modern methods of pharmaceutical analysis is instrumental methods, including spectral one.
Results and discussion
During previous studies, we have developed a method of spectrophotometric determination of hypertril substance. The studies showed that the absorption curves in the UV region of our and standard designs are identical and absorption maxima coincide. For the qualitative and quantitative determination of hypertril in tablet weight, a spectrophotometric determination method was approbated. Also it was developed and used to standardize hypertril substance.
Identification of the substance in hypertril tablet weight by spectrophotometry.
We measure the optical spissitude of the prepared solution of hypertril tablet weight.
Preparation of standard solution (comparison solution). We measure the optical spissitude of the standard sample at a wavelength λ = 258 nm. As a standard substance we use hypertril sample (state owned enterprise "Plant of chemical reagent" of Science and Technology Complex "Institute for Single Crystals " NAS of Ukraine), which meets the requirements of quality control methods. Terms of spectrophotometric determination.
Optical spissitude measurement of solutions was held by scanning spectrophotometer Optizen POP, relatively solvent water, the thickness of the cuvette -1 cm, wavelength λ = 258 nm. As a result of our research the methodology of standardization of hypertril in tablet weight was designed by spectrophotometry method that is simple and easy in execution, replicable and meets all the requirements of the State Pharmacopoeia and international standards.
Findings
As a result of research, we developed a sensitive, objective, reliable and reproducible method for the spectrophotometric determination of hypertril in the tablet mass.
References
- Belenichev I.F., Kucherenko L.I., Volchik Yu.A., Abramov A.V., Buhtiyarova N.V. Some aspects of cardioprotective activity of new b-adrenoblocker with NO-mimetic effect «Hypertril» on myocardial infarction model. Farmakologiya ta likarska toksikologiya 2014; 4–5 (40): 11-16
- Georgievskiy G.V. Development of the complex physical and chemical methods, ensuring the creation and control of the quality of the original domestic products, 1,2,4-triazole. Zaporozhskiy meditsinskiy zhurnal 2011; 13(1): 58–69.
- Derzhavna Farmakopeia Ukrainy [State Ukrainian Pharmacopeia]. Kharkiv, 2; 2008: 620.
- Kucherenko L.I., Hromilova O.V., Moryak Z.B., Tkachenko G.I., Vaschenko O.V. Stage control of tablets manufacturing. Aktualni pitannya farmatsevtichnoi i medichnoi nauki ta praktiki 2014; #2: 31-34.
- 5. Mazur I.A, Belenichev I.F., Chekman I.S. Using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) as an active base of drug preparations for correcting dysfunctions of the nitroxydergic system of target organs accompanying homocysteinemia and acute cerebrovascular disorders. Patent RU 2 532 394, 2013.
- Mazur I.A, Belenichev I.F., Chekman I.S. Using of 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide as an active bast of medical agents for correction of nitroxidergic system dysfunction atherosclerosis and diabetes mellitus. Patent UA 84351, 2013
- Mazur I.A., Chekman I.S., Belenichev I.F., Voloshin N.A. Metabolitotropnyie preparati. Zaporozhe, 2007: 304.
- European Pharmacopoeia.Strasbourg: Сouncil ofEurope 2007: 1100.
- Sevgi T.U.,Fikriye T.E. Spectrophotometric method for the determination, validation, spectroscopic and thermal analysis of diphenhydramine in pharmaceutical preparation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2010; 77: 324–329.
- White W. Blood pressure monitoring in cardiovascular medicine and therapeutics.New Jersey: Humana Press 2011: 308.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal .
- Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).